Piramal Alternatives invested Rs 110 crore in Noida-based Biodeal Pharmaceuticals through convertible instruments. The funding will enhance infrastructure, technology, and a nutraceuticals manufacturing facility. Biodeal is a key contract manufacturing player, specializing in nasal sprays and achieving PIC/S approval.
Piramal Alternatives, the fund management arm of the Piramal Group, has announced a Rs 110-crore ($13.2 million) investment in Noida-based Biodeal Pharmaceuticals, a contract development ..